Insight on Pharmaceuticals and Healthcare

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Report
Report

Myelodysplastic Syndrome: An Underserved Population Offers Commercial Opportunity

SuperGen/MGI Pharma's Dacogen and Celgene's Revlimid are in pre-registration for treatment of myelodysplastic syndrome (MDS). However, a significant proportion of the MDS population will be left underserved by pharmacotherapy.

Published By Datamonitor
18 Oct 2005 $1900
Buy
Report
Report

Monoclonal Antibodies: 2010

Historical and forecast analysis of the monoclonal antibodies sector from 2003 through to 2015.

Published By Datamonitor
07 Oct 2010 $2800
Buy
Report
Report

Generics Market Outlook: 2015

Forecast and historical assessment of the generics market from 2005 to 2015

Published By Datamonitor
15 Oct 2010 $2800
Buy
Report
Report

Pipeline and Commercial Insight: Pneumococcal and Meningococcal Vaccines

This report explores key issues in pneumo-and meningococcal vaccines the seven major markets. It contains an analysis of epidemiological trends, in-depth assessment of currently marketed and pipeline vaccines and a ten-year sales forecast.

Published By Datamonitor
19 Oct 2010 $6400
Buy
Report
Report

Infectious Diseases Vaccine Market Overview

This report provides an overview of the vaccines industry with detailed profiles of the 5 major vaccine companies. It analyzes trends, sales, R&D and licensing strategies, portfolios and pipelines as well as other individual strengths & weaknesses.

Published By Datamonitor
25 Oct 2010 $6400
Buy
Report
Report

Pipeline Insight: Moderate-to-Severe Acute Pain - Positive outlook for opioid-sparing analgesics

Analysis of the future moderate to severe acute pain market with sales forecasts to 2019 across the seven major markets (US, Japan, 5EU) of key brands, generics, and pipeline products.

Published By Datamonitor
01 Nov 2010 $6400
Buy
Report
Report

Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative) - Triple-negative breast cancer offers a significant opportunity to new market entrants while Herceptin dominates the HER-2-positive market

Primary research-based analysis of the hormone receptor-positive breast cancer market. Includes epidemiology, patient segmentation, treatment trends, and future treatment scenarios. Separate coverage of triple-negative and HER-2-positive subsets.

Published By Datamonitor
03 Nov 2010 $6400
Buy
Report
Report

King Pharmaceuticals Inc.: PharmaVitae Profile

Analysis of King's corporate strategy, marketed portfolio, pipeline potential and financial position in 2009 and to 2015

Published By Datamonitor
11 Nov 2010 $2800
Buy
Report
Report

Pharmaceutical Licensing and Alliances in the Asia-Pacific Region – Pharma enhances its focus on APAC markets

An overview of licensing and alliance trends in developed and emerging pharmaceutical markets in the Asia-Pacific region from Q3 2009 to Q2 2010, including discussion of the drivers of recent deals and analysis of key agreements.

Published By Datamonitor
19 Nov 2010 $2800
Buy
Report
Report

Stakeholder Opinions: Hepatocellular cancer

Stakeholder Opinions: Hepatocellular Cancer discusses issues in the treatment of hepatocellular cancer, highlighting potential target populations for drug developers, treatment limitations and unmet needs, and an overview of the current pipeline.

Published By Datamonitor
01 Dec 2010 $2800
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.